CAMBRIDGE, England, April 25, 2024 /PRNewswire/ — Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks…



Leave a Reply

Your email address will not be published. Required fields are marked *